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Question 
This briefing summarises the evidence on the facilitators 
and barriers to the uptake of low dead space injecting 
equipment from 1st January 2000 to 31st May 2021. 
 
Key messages 
The main facilitators to the uptake of low dead space 
(LDS) injecting equipment for people who inject drugs 
(PWID) are: 
• Provide accessible information about the beneficial 
features of LDS injecting equipment, such as less 
wasted drug and lower risk of transferring infections. 
Encourage PWID to use new equipment for every 
injection, but supplement this with instructions for 
proper rinsing and disinfection of equipment. 
• Ensure LDS injecting equipment is available for 
PWID to try alongside their current equipment. 
Gradual transition – make LDS equipment available 
and over time reduce the availability of high dead 
space equipment. 
• Place PWID at the heart of any further research into 
implementation of new equipment. 
• Make use of peer networks to share information 
among PWID, particularly positive experiences. 
• Train staff involved in the provision of needle and 
syringe programmes (NSP) in the benefits of LDS 
equipment, as well as how to respond to any safety, 
health or practical problems. 
• Any intervention should be viewed as a component 
of comprehensive harm reduction policies, not as a 
lone intervention. 
The main barriers to the uptake of LDS injecting 
equipment for PWID are: 
• Many PWID are happy with their current equipment 
and have not reported problems with injecting, so 
do not feel it is necessary to change. 
• Familiarity with current equipment and its place in 
the routine of injecting; length of time injecting. 
• The need to learn how to use new equipment. 
• Potential lack of availability of comparable 
equipment, such as size of barrel or length of 
needle. 
• Getting a 'hit' can sometimes be viewed as more 
important than harm prevention. 
Evidence briefings are a summary of 
the best available evidence that has 
been selected from research using a 
systematic and transparent method in 
order to answer a specific question. 
 
What doesn't this briefing do? 
The findings from research papers 
summarised here have not been quality 
assessed or critically appraised. This 
briefing is a neutral presentation of the 




Who is this briefing for? 
This briefing is for a Consultant in 
Health Protection for the purpose of 

























You may request any publications 






The information in this report 
summarises evidence from a literature 
search - it may not be representative of 
the whole body of evidence available. 
Although every effort is made to ensure 
that the information presented is 
accurate, articles and internet resources 
may contain errors or out of date 
information. No critical appraisal or 
quality assessment of individual articles 
has been performed. No responsibility 
can be accepted for any action taken on 









Information about this evidence 
briefing 
 
This briefing draws upon a literature 
search of the sources Embase, Ovid 
Medline, APA PsycInfo, Ovid 
Emcare, and the website IDPC.NET 
from 1st January 2000 to 31st May 
2021. 
 
23 highly relevant citations were 
used to produce this evidence 
briefing.  
17 additional papers were 
considered to be ‘of interest’ and 
details can be obtained on request. 
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'Dead space' is the space between the needle and the plunger that still has liquid in it 
following an injection; injecting equipment contains either low or high amounts of 
'dead space'. There is a growing body of evidence that suggests low dead space 
(LDS) injecting equipment may reduce the risk of bloodborne viruses and 
infections, such as HIV and hepatitis C, that are associated with sharing equipment 
(1). LDS injecting equipment includes low dead space syringes (LDSS), reduced 
dead space modified syringes and more recently developed, detachable low dead 
space needles. 
 
When people who inject drugs (PWID) share needles and syringes, the volume of 
dead space is an important determinant of the volume of blood that is transferred 
from one PWID to another (2). "The 'dead space' in syringes is a significant factor in 
both the dose of blood left in used syringes (less dead space = less virus), and the 
viral survival time (lower dead space = reduced viral survival)" (3) (p8). Traditional 
syringes with detachable needles are known as high dead space syringes (HDSS) 
and these transfer more blood if reused (4).  
 
The World Health Organization (WHO) recommends that: "needle and syringe 
programs […] provide low dead-space syringes for distribution to people who inject 
drugs" (5) (p8). For the UK, the National Institute for Health and Care Excellence 
(NICE) recommend that needle and syringe programme providers should, "make 
needles available in a range of lengths and gauges, provide syringes in a range of 
sizes and offer low dead-space equipment" (6). 
 
Needle and syringe programmes (NSPs) act as sites to supply sterile equipment 
to PWID with the aim of reducing the need to share or reuse injecting equipment. 
Sometimes equipment will still be reused or shared, so WHO's and NICE’s 
recommendations to provide LDSS are intended to protect people from infection.   
 
Facilitators to the uptake of low dead space injecting equipment 
 
"Informing people who inject drugs (PWID) about the beneficial 
features of less wasted drug and the lower risk of transferring 
infections is likely to support the acceptability of detachable LDSS 
as it recognises their priorities in regards to the properties of 
injecting equipment as well as the health benefits" (7) (p142). 
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Research undertaken at a needle and syringe service in Bristol (England) aimed to 
explore whether PWID were willing to switch to LDSS (1). Interviews were conducted 
with 23 PWID (15 men and 8 women) and 13 NSP volunteers and professionals (6 
men and 7 women) who work with them to gather views and insights into how to 
ensure the successful implementation of providing LDSS. PWID were invited to be 
on the project steering group, which was vital as they brought valuable insight and 
engagement.  
 
The research found support among PWID for LDSS. The most valuable benefit was, 
"less wasted drug, as there is less left in the syringe after injecting," as well as, "the 
lower risk of transferring infections" (1). Based on the findings of the research, the 
following recommendations have been made for introducing LDSS: 
• training staff involved in the provision of NSP on the benefits of LDSS and 
how to encourage behaviour change in PWID 
• education for PWID on the benefits of switching from HDSS 
• providing information both verbally and in written format 
• ensuring LDSS are available to try alongside usual equipment – gradual 
introduction of new equipment (1). 
 
It is suggested that these would be most effective during a targeted intervention in 
NSPs that incorporates training, education, persuasion and eventual restriction of 
HDSS to smooth the transition to LDSS. The authors also note that: "in staff 
members’ view, focusing on the benefits of equipment change in relation to drug use, 
rather than on the prevention of potential health risks was more likely to be effective" 
(8) (p103). 
 
Another project in Bristol found that, "people who inject drugs would be willing to 
switch to this safer equipment" (9). The project aimed to encourage the use of LDSS 
in NSPs and involved service users in co-designing materials including posters, a 
booklet and an animation. The researchers ran a consultation process with eight 
NSPs across the UK, "to understand barriers to the uptake of LDSS, and how 
different programmes operate and share harm reduction messages" (10) (p3). 
Workshops were run with 5 service users (3 men and 2 women) from a range of 
ages, with different experiences of injecting and equipment preferences. The 
audience for promoting the benefits of LDSS and broader harm reduction messages, 
was: PWID, NSPs (and their staff), and policymakers. 
 
The authors found that placing PWID at the heart of the research implementation 
project was shown to be essential, as it ensured the materials produced were 
appropriate and engaging. It was also important not to stigmatise or alienate the 
intended audience; PWID selected the design style and informed the language, 
messages and overall look of the designs. This meant that the designs "avoided 
images and language with negative connotations" and comments on the overall look 
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and feel of the designs were taken into account before they were finalised (10) (p1). 
The materials were launched at a public event in January 2019 and outcomes of this 
work are being monitored by the project team. 
 
Further work from this research team that was informed by behaviour change theory 
recommends that interventions should focus on increasing capability, opportunity 
and motivation of PWID to change to LDSS. Staff involved in the provision of NSP 
are advised to take 5 key actions: 
1. Undertake training about the benefits of low dead space syringes, how to 
identify barriers to change and ways to support changes in behaviour 
2. Provide accessible information and education to people who inject drugs to 
raise awareness of the benefits of low dead space syringes 
3. Use peer networks to spread information 
4. Make detachable low dead space syringes available, and over time reduce 
the availability of high dead space syringes 
5. Monitor and respond to any safety, health or practical problems which service 
users have using the new equipment (11) (p3). 
 
In 2015 Glasgow (Scotland) experienced an outbreak of HIV infection amongst 
PWID. 47 new diagnoses were recorded, compared to an annual average of around 
10 in PWID (12). Response to the outbreak was multi-agency and a key aspect was 
increasing availability of Injecting Equipment Provision (IEP) services and 
introducing detachable LDSS to PWID. It was identified that fixed-needle 1ml LDSS 
were available, but the majority of cases had recently accessed 2ml syringes from 
the IEP service. The standard design of these 2ml syringes was found to be 
incompatible with lower dead space needles, which necessitated a new design. A 
new LDSS was designed to fit all separate needles, which was "lab tested and 
shown to reduce 'post injection' blood and fluid content by 70%" (p140).  
 
Due to the considerable risk of further transmission during the outbreak, these new 
LDSS were introduced without training or promotion for PWID. Staff were briefed 
with information so that they could answer any questions that arose, but at the time 
of publication, the authors reported that no issues were identified by clients or staff in 
relation to the distribution or use of LDSS. A national procurement contract in 
Scotland for IEP equipment meant that the new LDSS were then rolled out across 
the country. This shows that when faced with a rapidly transmitting outbreak among 
PWID, replacing existing stock with new LDSS can be successful with minimal 
disruption to supply. 
 
A pilot study in Tajikistan across NSPs in two cities in 2015 aimed to assess: 
• the feasibility of NSPs distributing LDSS 
• whether LDSS was acceptable to the clients 
• any barriers to PWID using the needles 
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• which features of the LDSS might affect uptake (13). 
 
The research team identified that NSPs in Tajikistan were very busy and only had 
access to limited resources. To mitigate the need for extensive staff training, the 
authors of the study created a one-page flyer that promoted the benefits of LDSS 
(specifically detachable needles) for staff involved in the provision of NSP to 
distribute alongside the equipment. Distributing a flyer was considered to be a low-
intensity intervention. 
 
The flyer emphasised several advantages of LDS detachable needles, which were 
informed by previous research into the values and beliefs of PWID in Tajikistan: 
1. LDS detachable needles reduce the amount of drug that is retained and 
wasted in the dead space 
2. LDS detachable needles facilitate accurate division of drug solution between 
two PWID 
3. LDS detachable needles reduce the volume of blood retained in a needle and 
syringe after use, which may decrease the risk of HIV and HCV transmission 
if they are shared (13) (p4). 
 
Both NSP locations distributed the flyer and needles without difficulty, in place of the 
usual HDS needles. Findings from the study suggested that at follow-up, almost all 
use of HDS needles were because participants were unable to obtain LDS 
detachable needles. The findings also highlight the importance of selecting 
interventions that are compatible with the beliefs of both PWID and staff involved in 
the provision of NSP. Acceptability is the most important factor with the intended 
recipients, and not the implementation of a solution that strives to be perfect.  
 
A study that considered how to reduce the burden of exposure to infections through 
sharing needles recommended that the distribution of LDS syringes and needles is 
accompanied by instructions for proper rinsing and disinfection of equipment. This is 
not to encourage sharing of equipment, but to reduce transmission of viral or 
infectious loads and chances of the needles clogging (14). 
 
A social marketing intervention took place as a pilot programme over 1 year in 
Vietnam (15). This involved distributing LDSS through both pharmacies as well as 
non-pharmacy outlets. If LDSS were already available at pharmacies, the project 
focused on improving late-night access to LDSS by establishing new non-pharmacy 
outlets. Results showed a positive association between LDSS use and exposure to 
social marketing activities. The programme used print materials, community events 
and face-to-face communication tools to promote the benefits of LDSS, particularly 
emphasising less pain and scarring due to high quality of  the needle, and less drug 
loss due to LDS. Distribution channels included tea stalls, coffee shops, truck 
stations, motorcycle taxi drivers, and pharmacies near shooting galleries. The 
What are the facilitators and barriers to the uptake of low dead space injecting equipment for 
people who inject drugs? 
 
KLS Evidence Briefing  17th June 2021 
 
authors also found that, "LDSS use had a stronger association with perceptions of 
LDSS product quality than with perceptions regarding LDSS potential to reduce HIV 
transmission risk and use" (p1). 
 
Participants in another study in Tajikistan (6 focus groups with a total of 100 
participants) reiterated the importance of having good quality needles, particularly 
needles that are sharp and securely attached to the plastic hub (16). Sharp needles 
are less painful, and do less damage to veins. If the quality of LDSS is assured, this 
may mean that PWID are more likely to use them. 
 
An economic analysis that modelled the use of detachable LDSS over 10 years 
showed potential increased costs (£0.008) per syringe and increased yearly staff 
training costs (£536) but an estimated decreased risk (by 47.5%) of hepatitis C virus 
(HCV) transmission compared with HDSS, which would result in considerable 
savings in HCV-related treatment and care costs. "Overall cost savings were 
£4,116,401 over 50 years and [quality-adjusted life year] gains were 1000, with an 
estimated 30% reduction in new infections over the 10-year intervention period" (17) 
(p702). The study was based on an NSP in Bristol, England and found that a gradual 
transition towards detachable LDSS would enhance acceptability in PWID, 
supported by providing information about the reasons for the introduction of the 
equipment. 
 
In respect to this analysis, another factor to consider regarding uptake of LDSS is 
how to ensure that PWID have a sufficient supply of sterile equipment. Some data 
illustrates that three or more attempts can sometimes be necessary to obtain an 
injection, which means that multiple LDSS would need to be provided for each 
injection (18). 
 
A response from the authors of the economic analysis suggests that: "a complete 
switch in equipment available across all NSP providers would reach all PWID, 
including the most marginalised, who may not access services directly (i.e. rely upon 
secondary distribution from peers)" (19).  
 
It is noted that encouraging PWID to use LDSS should be viewed as a component of 
comprehensive harm reduction policies, and not as a lone intervention (4). 
 
"The provision of LDSS needs to occur alongside innovation within needle and 
syringe programmes (NSP) to ensure that unrestricted provision of injecting 
equipment and safe injecting advice reach underserved populations and those 
disengaged from services. LDSS must therefore be considered part of an integrated 
approach to alleviate social exclusion and reduce health inequalities faced by PWID" 
(18) (p714). 
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Barriers to the uptake of low dead space injecting equipment 
 
There are several barriers that arise in the literature when considering how to 
encourage PWID to change from HDSS to LDSS.  
 
In interviews with 23 PWID (15 men and 8 women) in Bath and Bristol, England, 
respondents indicated that they put trust in their friends or acquaintances, so early 
experiences of injecting often influences their current practice (8). A person who has 
witnessed their peers successfully using HDSS and gone on to do the same in their 
own practices may show some reluctance to change.  
 
Further reluctance to change has been cited as a factor if a person has not had any 
problems with their current practice, as there is no impetus to change (8). The length 
of time a person has been injecting also affects willingness to change. 
 
Most people interviewed found it difficult to change injecting equipment (1). Reasons 
for this included continuity and familiarity as being an important part of their routine. 
Some referred to their injecting practice as a 'ritual' that provided a sense of control. 
One interviewee suggested that there was some fear and wariness about the 
unknown of new equipment, and whether they would be able to successfully inject 
with different equipment. This is related to the potential loss or waste of drug, as well 
as potential for causing harm or pain with unknown equipment. 
 
"The prioritisation of getting a hit quickly over the prevention of future problems was 
identified explicitly by staff and more implicitly by PWID as an important barrier to 
change" (8) (p103). Familiarity with current equipment may mean that it can be used 
more quickly and effectively, and thus discourage PWID from changing equipment. 
 
Geographical differences in injecting practices have been highlighted as a barrier to 
change, as any interventions would need to be highly tailored to local drug types and 
injecting practices (20). For example, techniques such as frontloading, backloading, 
using the storage syringe or sharing the load require a syringe with a high volume 
and a detachable needle (21). In addition, in some parts of the world HDSS are the 
only option available (22). 
 
Several articles discuss the availability and type of low dead space equipment that is 
available. One research project found that LDSS would not be acceptable to PWID 
who need larger syringes and longer and thicker needles that are detachable (13).  
 
Some PWID indicated a preference for their usual HDSS because they allow 
replacement of needles during an injection episode, which is sometimes necessary if 
a needle becomes blocked or blunt from repeated attempts to find a vein (16). Some 
PWID 'back-fill' syringes with heroin by removing the plunger and adding dry powder 
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directly into an empty barrel, which was difficult for those who had previously used 3 
ml or 5 ml syringes (20). These perceptions highlight incomplete knowledge about 
the availability of different LDS injecting equipment, including detachable needles 
(4).  
 
Injecting location is raised as another potential barrier. Examples include: 
• PWID that had injected into their groin were less likely to use LDSS  
• Those who had injected crack were less likely to use LDSS 
• Polydrug use was negatively associated with LDSS use (23). 
 
During the research project in Bristol mentioned previously, visits to NSPs revealed 
that not all NSPs are operated by dedicated workers. This highlights the need for 
updated standardised training to ensure that there is an awareness of the benefits of 
encouraging PWID to use LDSS where they are available (19). The authors also 
noted that in the Bristol NSP all injecting equipment is delivered through a single 
contract, so impact of any changes to provision is easier to assess. 
 
Lack of awareness of alternatives to HDSS has also been presented as an issue in 
encouraging uptake of LDSS. "The provision of LDSS needs to occur alongside 
innovation within needle and syringe programmes (NSP) to ensure that unrestricted 
provision of injecting equipment and safe injecting advice reach underserved 





At the time of writing in 2021, the availability and distribution of equipment in the UK 
differs from much of the literature included in this evidence briefing. More 
manufacturers have developed different products and access to detachable LDS 
equipment (in various forms) is much more widespread. Use of LDS equipment is 
likely to be more familiar to both service users and staff. The barrier for use of LDS 
relating to injecting practices requiring replaceable needles may no longer apply to 
users in the UK. 
 
It is also noted that further research and epidemiological evidence would be 
beneficial to demonstrate the effectiveness of LDS equipment in reducing 
transmission of HCV and HIV at a population level (18).  
  
What are the facilitators and barriers to the uptake of low dead space injecting equipment for people who inject drugs? 
 
KLS Evidence Briefing  17th June 2021 
 


















• Low dead space injecting equipment 
• People who inject drugs 
 
Exclusion criteria 
• Papers not in English 
• Focused on healthcare use of low dead space 
injecting equipment 
• Focused on high dead space equipment 




1     ("low dead space" or LDSS).tw. 
2     "fixed needle and syringe".tw. 
3     low dead space syringe/  
4     1 or 2 or 3  
Date limit: 2000 – current 
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